Contineum Therapeutics (CTNM) Operating Margin (2023)
Contineum Therapeutics has reported Operating Margin over the past 1 years, most recently at 77.87% for Q2 2023.
- Quarterly results put Operating Margin at 77.87% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 22.52% (changed N/A YoY), and the annual figure for FY2023 was 32.15%, changed.
- Operating Margin for Q2 2023 was 77.87% at Contineum Therapeutics, down from 5559.78% in the prior quarter.
- Over the last five years, Operating Margin for CTNM hit a ceiling of 5559.78% in Q1 2023 and a floor of 77.87% in Q2 2023.